IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TARAMASSO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.281
AS - Asia 3.966
EU - Europa 3.399
SA - Sud America 494
AF - Africa 122
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.949
SG - Singapore 1.247
CN - Cina 1.031
IT - Italia 948
GB - Regno Unito 678
VN - Vietnam 466
BR - Brasile 385
HK - Hong Kong 363
DE - Germania 321
RU - Federazione Russa 318
BD - Bangladesh 296
CA - Canada 270
SE - Svezia 225
FR - Francia 223
IE - Irlanda 191
IN - India 177
NL - Olanda 128
ID - Indonesia 122
FI - Finlandia 81
ES - Italia 50
JP - Giappone 43
UA - Ucraina 42
DK - Danimarca 41
AR - Argentina 36
KR - Corea 34
CI - Costa d'Avorio 33
ZA - Sudafrica 33
TR - Turchia 28
AT - Austria 27
AU - Australia 27
MX - Messico 26
PL - Polonia 26
BE - Belgio 25
IQ - Iraq 24
PH - Filippine 16
EC - Ecuador 15
PK - Pakistan 14
TW - Taiwan 14
CH - Svizzera 13
CO - Colombia 12
CL - Cile 11
PY - Paraguay 11
PE - Perù 10
UZ - Uzbekistan 10
GR - Grecia 9
SA - Arabia Saudita 9
CR - Costa Rica 8
ET - Etiopia 8
MY - Malesia 8
KE - Kenya 7
AZ - Azerbaigian 6
MA - Marocco 6
NP - Nepal 6
RO - Romania 6
TN - Tunisia 6
UY - Uruguay 6
CZ - Repubblica Ceca 5
JM - Giamaica 5
JO - Giordania 5
KZ - Kazakistan 5
LT - Lituania 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TH - Thailandia 5
VE - Venezuela 5
BG - Bulgaria 4
BY - Bielorussia 4
IL - Israele 4
NG - Nigeria 4
NO - Norvegia 4
AL - Albania 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
LA - Repubblica Popolare Democratica del Laos 3
OM - Oman 3
PA - Panama 3
SI - Slovenia 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
DZ - Algeria 2
EE - Estonia 2
GH - Ghana 2
HR - Croazia 2
HU - Ungheria 2
LB - Libano 2
LY - Libia 2
PT - Portogallo 2
RS - Serbia 2
SC - Seychelles 2
SD - Sudan 2
SN - Senegal 2
Totale 12.262
Salva come PNG Salva come JPEG
Città #
Singapore 726
Southend 530
Ashburn 453
Chandler 342
San Jose 306
Hong Kong 290
Dallas 283
Milan 224
Dublin 189
Beijing 180
Council Bluffs 173
Fairfield 169
Princeton 161
Frankfurt am Main 150
Toronto 141
Ho Chi Minh City 137
Los Angeles 123
Hanoi 113
Santa Clara 107
Wilmington 100
Seattle 91
Jakarta 89
Lauterbourg 88
Buffalo 83
New York 83
Bengaluru 82
Houston 77
Ann Arbor 75
Ottawa 71
Woodbridge 71
Rome 68
Helsinki 67
Des Moines 66
Boardman 63
Hanover 63
Hefei 63
Cambridge 54
Central District 51
Guangzhou 48
Turin 48
Redwood City 47
Moscow 42
Phoenix 34
Abidjan 33
São Paulo 33
Shanghai 30
Seoul 27
Naples 26
Da Nang 25
Tokyo 24
Chicago 23
Cangzhou 22
London 22
Nanjing 22
Shenzhen 22
Amsterdam 21
Columbus 20
Nuremberg 20
Vienna 20
Bologna 19
Genoa 19
Belo Horizonte 18
Montreal 18
San Diego 18
City of London 17
Dearborn 17
Palermo 17
The Dalles 16
Baghdad 15
Jinan 15
Madrid 15
Redondo Beach 15
Dong Ket 14
Tianjin 14
Warsaw 14
Florence 13
Hangzhou 13
Mumbai 13
Rio de Janeiro 13
Washington 13
Atlanta 12
Berlin 12
Biên Hòa 12
Boston 12
Falls Church 12
Munich 12
San Francisco 12
Brussels 11
Chennai 11
Düsseldorf 11
Haiphong 11
Kent 11
Brooklyn 10
Eau Claire 10
Fuzhou 10
Bracknell 9
Manchester 9
Mexico City 9
Quanzhou 9
Shenyang 9
Totale 7.351
Salva come PNG Salva come JPEG
Nome #
Aumento del peso nelle persone che vivono con infezione da HIV: ritorno al benessere o effetto indesiderato della terapia antiretrovirale? = Weight gain in people living with HIV infection : return to health or adverse event of antiretroviral therapy? 438
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study 354
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 315
Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer 262
Integrase inhibitors use and CMV infection predict immune recovery in peolple living with HIV starting first-line therapy 218
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 217
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo 212
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors : results from a large observational cohort study (SCOLTA) 211
HIV-associated neurocognitive impairment in the modern ART era : are we close to discovering reliable biomarkers in the setting of virological suppression? 209
Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV 207
Pillars of long-term antiretroviral therapy success 195
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 193
Onychomadesis in a male patient with secondary syphilis 188
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 185
Treatment simplification to atazanavir/ritonavir plus lamivudine versus maintenance of atazanavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in virologically-suppressed HIV-1-infected patients : 48-weeks results from a randomized trial (ATLAS-M) 179
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 179
CD8+CD28-CD127loCD39+regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection? 178
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced dimalsease: a trial emulation 171
HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes 164
Weight Gain : A Possible Side Effect of All Antiretrovirals 162
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia 161
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 157
Pneumocystis jirovecii pneumonia in HIV-negative patients, a frequently overlooked problem. A case series from a large Italian center 148
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection 147
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy 145
Increasing use and accessibility of anti parasitic drugs for migrants with neglected diseases at a time of migratory emergency 145
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study 144
Maintenance of viral suppression after optimization therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in HIV-1-infected patients 143
Predictors of weight gain in patients treated with dolutegravir 141
Bloodstream infections in HIV-infected patients 139
Time to change the single-centre approach to management of patients with tuberculosis : a novel network platform with automatic data import and data sharing 138
Bloodstream infections in patients living with HIV in the modern cART era 136
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 135
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions : a regional simulation 134
Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents : A 10-Year Observational Study 134
Ibalizumab and fostemsavir in the management of heavily pre-treated HIV-infected patients 133
Missed opportunities to prevent mother-to-child transmission of HIV in Italy 133
Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy 133
Bedaquiline : a new hope for shorter and better anti-tuberculosis regimens 133
Starting HIV therapy in patients with mitochondrial disease 133
Case report : management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir 132
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area 132
Duration of isolation and precautions in immunocompromised patients with COVID-19 132
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 131
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides 131
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500,000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study 128
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV 127
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 126
Will new antimicrobials overcome resistance among Gram-negatives? 126
Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view 120
Chemotherapy Mass Campaigns and Migratory Flows : An Unexpected Connection 119
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study 119
Role of raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents 115
Immunonutrition in human immunodeficiency virus infection : which populations to target? 115
Short Communication : Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis? 114
Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells 114
HIV infection among adolescents and young adults in Italy: epidemiology, viro-immunological and treatment outcomes 114
Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital : a 30-year retrospective study 113
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV 112
Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era : Neglected no more? 111
Factors associated with hospital admission for COVID-19 in HIV patients 111
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 111
Tigecycline use in hospital and its potential role in infection control 110
How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis 110
The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen 108
Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study 107
Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience 105
Hypertensive versus HIV-infected patients : Who has the greatest target organ damage? Comparison of carotid plaque prevalence, intima media thickness and renal resistive index in the two groups of patients 101
Incident diabetes in course of antiretroviral therapy 100
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change? 100
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir 99
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 95
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status 94
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice : the results from HIV-HY study 92
Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients? 91
Reducing CD4+ lymphocyte cell monitoring in HIV-1 stable patients: a forecast of the cost saving 91
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda 89
Immunological profile of an infant treated with integrase inhibitor from the neonatal period 87
Treatment of hepatitis C virus genotype 4 in the DAA era 84
Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment 82
Rationale for an association between PD1 checkpoint inhibition and therapeutic vaccination against HIV 82
Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine : Data from the SCOLTA project 81
How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy 79
L’insufficienza tricuspidale funzionale: un’entità clinica di crescente importanza 75
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection : Much Ado About Nothing? 73
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 72
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals 71
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? 70
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen 65
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients : The HIV and Hypertension Study 64
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey 63
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B 62
Pineal Germinoma in a Child with Interferon-γ Receptor 1 Deficiency : Case Report and Literature Review 61
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient 60
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 60
Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports 54
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature 51
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis? 31
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 21
A machine learning-derived cardiovascular risk score in people with HIV: the ML-ICONA score 10
Totale 12.852
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202187 0 0 0 0 0 0 0 0 0 0 0 87
2021/20221.111 83 59 69 85 55 32 61 145 188 93 30 211
2022/20231.237 154 132 83 151 119 235 37 62 110 27 105 22
2023/2024851 25 77 28 52 174 96 47 59 24 40 108 121
2024/20252.135 66 193 64 188 251 104 61 204 153 178 217 456
2025/20265.510 477 386 566 480 434 321 672 253 571 486 585 279
Totale 12.852